1. Up Front

   Up Front 24 January 2023 Pages: 411 - 412

   

2. The changing landscape of scientific communication at EASD

   • Chantal Mathieu
   • Eleanor Kennedy
   • Hindrik Mulder

   Editorial 16 December 2022 Pages: 413 - 414

3. Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies

   • Stephen R. Karpen
   • Jessica L. Dunne
   • on behalf of the Type 1 Diabetes Consortium

   Review 22 July 2022 Pages: 415 - 424

   

4. Cardiovascular outcomes in type 1 and type 2 diabetes

   • Annika Rosengren
   • Pigi Dikaiou

   Review Open access 14 January 2023 Pages: 425 - 437

   

5. Identification of monogenic variants in more than ten per cent of children without type 1 diabetes-related autoantibodies at diagnosis in the Finnish Pediatric Diabetes Register

   • Minna Harsunen
   • Jarno L. T. Kettunen
   • Tiinamaija Tuomi

   Article Open access 23 November 2022 Pages: 438 - 449

   

6. Exercise as a non-pharmacological intervention to protect pancreatic beta cells in individuals with type 1 and type 2 diabetes

   • Alexandra Coomans de Brachène
   • Corentin Scoubeau
   • Decio L. Eizirik

   Article 19 November 2022 Pages: 450 - 460

   

7. Timing of physical activity in relation to liver fat content and insulin resistance

   • Jeroen H. P. M. van der Velde
   • Sebastiaan C. Boone
   • Renée de Mutsert

   Article Open access 01 November 2022 Pages: 461 - 471

   

8. Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study

   • Banafsheh Arshi
   • Jinluan Chen
   • Maryam Kavousi

   Article Open access 08 November 2022 Pages: 472 - 481

   

9. Kidney function measures and cardiovascular outcomes in people with diabetes: the Hoorn Diabetes Care System cohort

   • Elisa Dal Canto
   • Petra J. M. Elders
   • Joline W. J. Beulens

   Article Open access 08 November 2022 Pages: 482 - 494

   

10. High-throughput genetic clustering of type 2 diabetes loci reveals heterogeneous mechanistic pathways of metabolic disease

    • Hyunkyung Kim
    • Kenneth E. Westerman
    • Miriam S. Udler

    Article 20 December 2022 Pages: 495 - 507

    

11. The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes

    • Ele Ferrannini
    • Andrea Mari
    • Carmella Evans-Molina

    Article Open access 02 December 2022 Pages: 508 - 519

    

12. Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering

    • Sejal Mistry
    • Ramkiran Gouripeddi
    • Julio C. Facelli

    Article 30 November 2022 Pages: 520 - 534

    

13. Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes

    • Xiaona Cui
    • Jin Feng
    • Tianpei Hong

    Article Open access 04 November 2022 Pages: 535 - 550

    

14. Gene expression profiling in NOD mice reveals that B cells are highly educated by the pancreatic environment during autoimmune diabetes

    • Joanne Boldison
    • Jessica R. Hopkinson
    • F. Susan Wong

    Article Open access 12 December 2022 Pages: 551 - 566

    

15. Distinct subcellular localisation of intramyocellular lipids and reduced PKCε/PKCθ activity preserve muscle insulin sensitivity in exercise-trained mice

    • Rafael C. Gaspar
    • Kun Lyu
    • Gerald I. Shulman

    Article 01 December 2022 Pages: 567 - 578

    

16. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy

    • Haifa Maalmi
    • Alexander Strom
    • the GDS Group

    Article Open access 06 December 2022 Pages: 579 - 589

    

17. CCR2-positive monocytes contribute to the pathogenesis of early diabetic retinopathy in mice

    • Aicha Saadane
    • Alexander A. Veenstra
    • Timothy S. Kern

    Article Open access 26 January 2023 Pages: 590 - 602

    

18. Utility of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies: a viewpoint from the FDA

    • Justin Penzenstadler
    • Justin C. Earp
    • Kristen Pluchino

    Letter 21 December 2022 Pages: 603 - 604

19. GLP1RAs vs SGLT2is were associated with lower risk of major adverse limb events and similar risks of heart failure hospitalisation and stroke?

    • Lixin Du
    • Pan Wang
    • Jianlan Ma

    Letter 18 November 2022 Pages: 605 - 606